Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
COMMENTARY
COMMENTARY／Gov't to Cut Social Security Spending by \220 Bil by Promoting Use of Generics
Promotion of the use of generics is expected to become one of the major measures to be taken by the government to cut natural increases in social security-related spending by \220 billion in the budget formation for FY2009. Some members…
To read the full story
COMMENTARY
- As Japan’s Contract Drug Rep Ratio Rises, Expectations Grow for Specialist Talent and Flexible Workforce
August 5, 2025
- Pharmaceutical Policy at a Crossroad amid Political Upheaval in Japan
July 28, 2025
- Taking on Solid Tumors - 9: ADCs Surge Ahead as TCEs Strive for a Foothold
July 18, 2025
- FY2024 Sees Divergence in I/O Drug Sales, Keytruda Thrives while Rivals Face Pricing Headwinds
July 4, 2025
- Honebuto 2025 Approved - The Real Battle for Pharma Lies Ahead
June 23, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…